Universal Health Services, Inc (NYSE: UHS) Hogging The Spotlight Today

Currently, there are 57.19M common shares owned by the public and among those 53.87M shares have been available to trade.

The company’s stock has a 5-day price change of -5.93% and 2.62% over the past three months. UHS shares are trading 3.78% year to date (YTD), with the 12-month market performance up to 3.34% higher. It has a 12-month low price of $153.99 and touched a high of $243.25 over the same period. UHS has an average intraday trading volume of 951.01K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.37%, 3.13%, and -5.98% respectively.

Institutional ownership of Universal Health Services, Inc (NYSE: UHS) shares accounts for 85.12% of the company’s 57.19M shares outstanding.

It has a market capitalization of $12.00B and a beta (3y monthly) value of 1.31. The stock’s trailing 12-month PE ratio is 10.46, while the earnings-per-share (ttm) stands at $17.81. The company has a PEG of 0.82 and a Quick Ratio of 1.23 with the debt-to-equity ratio at 0.75. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.23% over the week and 2.22% over the month.

Earnings per share for the fiscal year are expected to increase by 17.89%, and 9.59% over the next financial year. EPS should shrink at an annualized rate of 12.77% over the next five years, compared to 13.00% over the past 5-year period.

Looking at the support for the UHS, a number of firms have released research notes about the stock. Robert W. Baird stated their Neutral rating for the stock in a research note on April 15, 2025, with the firm’s price target at $224. Morgan Stanley coverage for the Universal Health Services, Inc (UHS) stock in a research note released on March 26, 2025 offered a Equal-Weight rating with a price target of $200. Cantor Fitzgerald was of a view on February 03, 2025 that the stock is Overweight, while JP Morgan gave the stock Neutral rating on December 17, 2024, issuing a price target of $226. Goldman on their part issued Neutral rating on December 16, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.